Navigation Links
GVHD in Medical News

REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting

Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the Am...

TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients

The outcome of bone marrow transplant could be determined in just one week by measuring levels of a protein called tumor necrosis factor (TNF). // The inflammatory marker can help doctors identify which patients will develop graft vs. host disease (GVHD), the most commonly observed complication fol...

DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

Damon Runyon Cancer Research Foundation awards $2.7M to 7 top young clinical investigators

... disease (GvHD) in cancer patients treated with bone marrow transplantation. His hypothesis is that regulatory T cells (Treg) can be used to suppress gvhd while preserving beneficial anti-tumor immunity. This work could have significant translational implications by reducing GvHD-associated mortality, t...

DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease

...dpoints such as the proportion of patients free of gvhd at Day 50 (p-value 0.05) and Day 80 (p-value 0.005...he clinically relevant determination of whether GI gvhd patients at Day 30 (the end of treatment) had a durable gvhd treatment response as measured by whether or not t...

UNC study hints at new approaches to prevent transplant rejection

...lung and skin. Not only did these findings implicate TH17 cells in the disease, but they also generated one of the first mouse models to display acute gvhd skin changes consistent with the most common manifestations of the disease in humans. Having identified the role TH17 cells play in the disease, ...

New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow, Stem Cell Transplants

...ment appears to be safe and effective in combating gvhd -- with about 40 percent of the patients showing c... Annual Scientific Meeting in Washington, D.C. gvhd is a common complication of an allogeneic bone mar...n, according to the National Institutes of Health. gvhd is the term used when a donor's immune cells attac...

New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients

...ts 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with gvhd or those with hematologic malignancies with prolonged neutropenia from chemotherapy. In October 2006, the FDA approved NOXAFIL Oral Suspension for t...

Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study

...e outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic gvhd resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop...

ATIR Classified as "Cell Based" Medicinal Product by the EMEA

...s Pharma. About ATIR ATIR is designed to prevent life-threatening acute gvhd by eliminating the immune cells from the donor graft that otherwise attack ...wing rapid and safe donor immune reconstitution post transplantation. Acute gvhd is a major complication of allogeneic bone marrow transplantations. By prev...
GVHD in Medical Technology

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmato...

DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

...titution following a mismatched bone marrow transplantation. Nineteen end stage blood cancer patients were treated with no cases of grade III/IV acute gvhd occurring within the first 100 days after ATIR(TM) infusion, showing the feasibility and tolerability of the addition of ATIR(TM) in combination with ...

Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany

.... About ATIR(TM) ATIR(TM) is designed to prevent life-threatening acute gvhd by eliminating the immune cells from the donor graft that otherwise attack ...wing rapid and safe donor immune reconstitution post transplantation. Acute gvhd is a major complication of allogeneic bone marrow transplantations. By prev...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

...rding the potential use of orBec® for the treatment of gastrointestinal gvhd and the prospects for regulatory filings for orBec®. Where possible, DO... factors which may affect the future use of orBec® for gastrointestinal gvhd include the risks that: because orBec® did not achieve statistical sign...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

...rding the potential use of orBec® for the treatment of gastrointestinal gvhd and the prospects for regulatory filings for orBec®. Where possible, DO... factors which may affect the future use of orBec® for gastrointestinal gvhd include the risks that: because orBec® did not achieve statistical sign...
GVHD in Medical Dictionary

Graft Versus Host Disease

...lant against the patient", or " Graft - versus - Host " reaction. The complication is called " Graft - versus - Host Disease " (GvHD). What Types Of gvhd Exist? ... What is the risk for developing chronic graft - vs .- host disease (GVHD) after transplant? ... Diagnosis and Clinical Management...

Gastrointestinal

...e latest gastrointestinal , gastroenterology news headlines ... GastroIntestinal ... For OrBec(R) For The Treatment Of Chronic Gastrointestinal gvhd ... From screening and prevention to treatment of advanced gastrointestinal cancer, Fox Chase Cancer Center offers comprehensive care G...
GVHD in Biological News

Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes

Tampa, Fla. (July 21, 2008) Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD). GVHD occurs when an immune response is elicited by the grafted cells agains...

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models

...ts in the skin transplant model over Sirolimus single treatment. Likewise, gvhd mortality was reduced by the combination treatment. In addition, the combin...plans to file an Investigational New Drug (IND) for the prevention of acute gvhd associated with bone marrow transplantation later this year. The poster ...

U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment

...ife-threatening graft-versus-host-disease (GVHD). gvhd occurs when the immune cells within the donated cells attack the body of the transplant recipient. gvhd causes one-third of deaths after transplant. Rese...dels, T-regs will be a powerful therapy to prevent gvhd and enhance engraftment in transplant patients. O...
GVHD in Biological Technology

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the seco...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... that were observed were clearly of benefit to the gvhd patients," said Brian L. Hamilton, MD, PhD, Chief ...inal manifestation of GVHD, the organ system where gvhd is most frequently encountered and highly problema...Bec(R) is formulated for oral administration in GI gvhd patients as a single product consisting of two tab...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

...firmatory Phase 3 clinical trial of orBec(R) in GI gvhd under a Special Protocol Assessment (SPA) with the...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...ct the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that...

Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations

... transplant procedures. Nevertheless, no cases of severe grade III/IV acute gvhd occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a r... adequate immune reconstitution in combination with the prevention of acute gvhd in bone marrow transplantations using a mismatched donor. Dr. Denis-...

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

...key personnel to execute new clinical trials in GI gvhd and radiation enteritis. We are looking forward t...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...ct the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that...

DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors

...nfirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiation enteritis in the firs...nt factors which may affect the future use of orBec(R) for gastrointestinal gvhd include the risks that: the FDA's requirement that DOR conduct additional c...

DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer

...on. His research focus was in the immunobiology of gvhd in an animal model. He also spent several years as...3 completion in GI GVHD. His specific expertise in gvhd will be vital to the successful interaction betwee...al trial of orBec(R) for the treatment of acute GI gvhd and a Phase 1/2 clinical trial of DOR201 in radiat...

Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants

... uses stem cells removed from a donor) is graft-versus-host disease (GVHD). gvhd is a potentially fatal complication that can occur when mature donor T cell...destroy residual cancerous cells while avoiding or controlling the T cells' gvhd response." Dr. Friedman continues: "Our Vß spectratype analysis is a powe...

Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA

...velopment as a treatment for patients with chronic gvhd resistant or intolerant to immunosuppressive agent...TM) treatment targets activated T cells that cause gvhd and results in immune modulation within patients w... achieve disease remission. About chronic GvHD gvhd is a condition that can develop after allogeneic b...
Other Tags
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World Cup, ... at Sun Life Stadium in an international friendly. The World ... stars in the world of football in Colombian and Brazilian ... some of the best talent in the world in early ... team in the world according to the Fédération Internationale de ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... no way to guarantee that a surgical technique used to ... won,t increase the risk of spreading cancer to other parts ... The advisory panel to the Food and Drug Administration also ... laparoscopic power morcellation -- should sign a written consent stating ...
(Date:7/12/2014)... Response Management Systems is a crucial peak load management ... energy supply and demand. With the help of DRMS, ... increasing pressure on the grid) and replaced by Advanced ... and thermostats for load reduction. , DRMS is ... government mandates and benefits for energy efficiency and conservation ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... liver damage allegations continue to move forward in ... Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP ... 2014, U.S. District Judge Lawrence F. Stengel has ... Among other things, Judge Stengel found that the ...
(Date:7/12/2014)... 12, 2014 (HealthDay News) -- Burn injuries increase in the ... grills, say burn experts. Among those most vulnerable to these ... most vulnerable and often get burned by putting their hands ... director of the burn unit at Loyola University Medical Center ... "The old adage of ,When you play with fire, you ...
Breaking Medicine News(10 mins):Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
(Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
(Date:7/10/2014)... 2014  Acuity Market Intelligence today released forecasts from "The ... that the global market for National Electronic ID (eID) programs ... During this time, the number of National eID cards in ... Asia , with its vast population, will dominate ... issued, while Europe trails a distant ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
Other Contents